M. Wakefield

A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease

Mark Wakefield, Franck Durif, Erwan Bezard, 2016, Movement disorders : official journal of the Movement Disorder Society.

A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease

J. Tack, C. Keywood, M. Wakefield, 2009, Gut.

Metabotropic glutamate receptor 5: a target for migraine therapy

P. Goadsby, S. Akerman, Maggie W. Waung, 2016, Annals of clinical and translational neurology.